Epigenetic DNA Biomarkers Pinpoint Infertile Men and Predict Potential Success of Treatment
By LabMedica International staff writers Posted on 27 Nov 2019 |
Image: Human sperm stained for semen quality testing in the clinical laboratory (Photo courtesy of Wikimedia Commons)
A molecular analysis method was developed that identifies infertility in men through evaluation of genome wide alterations in sperm DNA methylation.
Male infertility is increasing and has been recognized as playing a key role in reproductive health and disease. The current primary diagnostic approach is to assess sperm quality associated with reduced sperm number and motility, which has been historically of limited success in separating fertile from infertile males.
An improved diagnostic approach, based on analysis of genome wide alterations in sperm DNA methylation, was described recently by investigators at Washington State University (Pullman, USA).
Results of this study pointed to a signature of differential DNA methylation regions (DMRs), which was associated with male infertility patients.
Since a promising therapeutic treatment of male infertility is the use of follicle stimulating hormone (FSH) analogs, which improve sperm numbers and motility in a sub-population of infertility patients, the investigators also sought other biomarkers among the infertile patients that could be used to predict who would be responsive to hormone therapy treatment. The investigators reported finding genome-wide DMRs associated with the patients that were responsive to FSH therapy versus those that were non-responsive. This novel use of epigenetic biomarkers to identify responsive versus non-responsive patient populations is anticipated to dramatically improve clinical trials and facilitate therapeutic treatment of male infertility patients.
"Male infertility is increasing worldwide and is recognized as playing a key role in reproductive health and disease," said senior author Dr. Michael Skinner, professor of biological sciences at Washington State University. "Having a diagnostic that tells you right away your male patient is infertile and here are the treatment options that will work for him would be immensely useful. We are interested in investigating a similar diagnostic for determining how patients with arthritis and neurodegenerative diseases such as autism will respond to different treatments. In the area of therapeutics where many of the drugs on the market only work for a fraction of patients, this could ultimately save time, money and facilitate much better healthcare management."
The infertility study was published in the November 14, 2019, online edition of the journal Scientific Reports.
Related Links:
Washington State University
Male infertility is increasing and has been recognized as playing a key role in reproductive health and disease. The current primary diagnostic approach is to assess sperm quality associated with reduced sperm number and motility, which has been historically of limited success in separating fertile from infertile males.
An improved diagnostic approach, based on analysis of genome wide alterations in sperm DNA methylation, was described recently by investigators at Washington State University (Pullman, USA).
Results of this study pointed to a signature of differential DNA methylation regions (DMRs), which was associated with male infertility patients.
Since a promising therapeutic treatment of male infertility is the use of follicle stimulating hormone (FSH) analogs, which improve sperm numbers and motility in a sub-population of infertility patients, the investigators also sought other biomarkers among the infertile patients that could be used to predict who would be responsive to hormone therapy treatment. The investigators reported finding genome-wide DMRs associated with the patients that were responsive to FSH therapy versus those that were non-responsive. This novel use of epigenetic biomarkers to identify responsive versus non-responsive patient populations is anticipated to dramatically improve clinical trials and facilitate therapeutic treatment of male infertility patients.
"Male infertility is increasing worldwide and is recognized as playing a key role in reproductive health and disease," said senior author Dr. Michael Skinner, professor of biological sciences at Washington State University. "Having a diagnostic that tells you right away your male patient is infertile and here are the treatment options that will work for him would be immensely useful. We are interested in investigating a similar diagnostic for determining how patients with arthritis and neurodegenerative diseases such as autism will respond to different treatments. In the area of therapeutics where many of the drugs on the market only work for a fraction of patients, this could ultimately save time, money and facilitate much better healthcare management."
The infertility study was published in the November 14, 2019, online edition of the journal Scientific Reports.
Related Links:
Washington State University
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders